45 results about "Preventing pain" patented technology

The invention relates to the technical field of medicines, in particular to application of tedizolid combined with fluconazole in preparation of antifungal drugs. The tedizolid and the fluconazole are combined for use, so that the antibacterial activity of the fluconazole on the candida albicans can be enhanced, a synergistic antifungal effect can be generated, and the drug resistance of the candida albicans on the fluconazole can be reversed.

The invention discloses a nursing device facilitating postoperative upper limb rehabilitation of an affected side after a breast cancer operation, and relates to the technical field of postoperative rehabilitation of the breast cancer. The nursing device convenient for the upper limb rehabilitation of the affected side after the breast cancer operation comprises a rack, an adjusting mechanism is arranged on one side of the rack, a rotating mechanism is arranged on one side of the adjusting mechanism, a massage mechanism is arranged on one side of the rotating mechanism, and an exercise mechanism is arranged on one side of the adjusting mechanism; the massage mechanism comprises two mounting plates, the two mounting plates are located on the two sides in the rack respectively, a connecting ring is fixedly connected to one side of each mounting plate, the inner wall of each connecting ring is arranged at the position sleeving the arm of the patient, and a cavity is formed in each connecting ring. Meanwhile, the rotating ball is enabled to perform pressing and rolling type massage operation on the arms of the patient, the side upper limbs of the patient can be exercised, pain of the patient due to muscle contraction can be avoided, and the effect of accelerating the rehabilitation progress of the patient is achieved.

The present invention discloses a compound of formula (I); specifically, the invention relates to a compound shown as a formula (I) or pharmaceutically acceptable salt, stereoisomer, prodrug, deuterated derivative or solvate, and application of the compounds in drugs for treating or preventing pain, gout, epilepsy, insomnia, anxiety disorder, depression, Parkinson's syndrome and other related diseases.

The present invention relates to compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4- (trifluoromethoxy)benzyl] amino }sulfonyl)benzoic acid (elismetrep; MT-8554), or a pharmaceutically acceptable salt thereof, for treating or preventing pain, particularly migraine or a trigeminal pain disease or condition such as medication overuse headache, cluster headache, general headache, trigeminal neuralgia, trigeminal neuropathy, trigeminal autonomic cephalalgia, orofacial pain, and dental pain.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

This invention belongs to the field of traditional Chinese medicine technology and discloses a traditional Chinese medicine composition for treating dysmenorrhea and its preparation method as a patch. Specifically, it relates to a traditional Chinese medicine composition for treating dysmenorrhea, comprising the following components in parts by weight: 10-14 parts of Ligusticum chuanxiong, 10-14 parts of Notopterygium incisum, 8-12 parts of processed myrrh, 2-6 parts of leech, 13-17 parts of processed Cyperus rotundus, 13-17 parts of Corydalis yanhusuo, 10-14 parts of earthworm, and 1-5 parts of dragon's blood. The traditional Chinese medicine composition for treating dysmenorrhea provided by this invention is based on the essence of the traditional Chinese medicine theory of "free flow prevents pain," with a rigorous combination of principal, assistant, and adjuvant herbs. The entire formula works synergistically to dispel wind and cold, invigorate blood circulation, remove blood stasis, regulate qi, and relieve pain, addressing both the symptoms and the root cause. After preparation as a patch, the medicine penetrates the skin and is absorbed through acupoints, resulting in rapid onset of action, convenient use, high safety, and good patient compliance. Clinical trials have shown that this invention has a good relieving effect on dysmenorrhea, with rapid onset and stable efficacy, overcoming many shortcomings of existing methods.

The present invention relates to a urinary incontinence clamp device for men utilizing magnetic force and, more particularly, to a urinary incontinence clamp device for men characterized in that, as a second clamp unit slides along an inner surface of a first clamp unit, the penis is gradually secured by a penile fixing portion, whereby the force applied to the penis is gradually exerted, reducing impact force applied to the penis, and thereby improving wearing comfort by preventing pain in the penis during fixation.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and / or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

The present disclosure relates to type I interferon inhibitors for treating or preventing pain associated with rheumatoid arthritis (RA) in a patient, related uses and kits, and methods for identifying patients having such pain and in need of treatment with such inhibitors.

The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (I), wherein: R1 is H, -OMe, Me, or one or more electron withdrawing groups; R2 and R3 are each independently H or alkyl or, taken together, form a 4- to 8-membered heterocyclic ring with the adjacent nitrogen atom; R4 is H or alkyl; R5 is H or one or more electron donating groups; and n is 1 to 4. The present disclosure further provides compositions comprising a therapeutically effective amount of a compound of general formula (I), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) such compositions to the subject.

The invention relates to a tetrahydrothebaine derivative as well as a preparation method and application thereof, in particular to a 7alpha-(4 '-substituted amidophenyl)-6alpha, 14alpha-endo-ethylidene (alkenyl)-tetrahydrothebaine derivative as shown in a general formula (I) or pharmaceutically acceptable salts thereof and a preparation method of the 7alpha-(4'-substituted amidophenyl)-6alpha, 14alpha-endo-ethylidene (alkenyl)-tetrahydrothebaine derivative. And to the use of such derivatives in the preparation of medicaments for the treatment and / or prevention of pain, irritable bowel syndrome, pruritus, addiction, depression. The derivative disclosed by the invention has a remarkable improvement effect in the aspects of agonistic activity of the kappa opioid receptor, subtype selectivity of the kappa opioid receptor and central safety.

A method for the treatment and / or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.

The invention discloses a geometric hypnosis platform (similar to a pillow), and relates to the technical field of sleep assisting equipment, in particular to a geometric hypnosis platform (similar to a pillow) which is specially designed for non-primary insomnia and insomnia cases affected by drugs, adopts physical regulation to help sleep, and does not depend on drugs and acupuncture. The supporting angle can be adjusted, the flat sleep is 12-20 degrees, and the side sleep is not more than 35 degrees; the acupoint adaptive design of replacing face with point is adopted to act on calming acupoints; the material is high-density anti-static rubber and plastic, and is anti-static, good in support and breathable; the pillow can reduce ear compression, prevent pain, fit the physiological curve of the cervical vertebra and reduce lesion risks. Scientific sleep conditions such as half saturation and fasting for four hours before sleep need to be matched for use. The whole device is designed according to the geometric principle, the angle structure is precisely matched with the human body, no static electricity stimulates nerves, a good sleep habit is developed, and related insomnia conditions are improved.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. Pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent, or excipient are also provided. Compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. In some embodiments, compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511124000359.jpg20170

A method of treating or preventing pain and / or inflammation and / or controlling pyrexia or fever, comprising administering (2S)-7-tert-butyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

The present invention discloses a kind of polysubstituted pyrrolidine derivative compounds represented by the formula (I), stereoisomers, tautomers, deutero-derivatives or pharmaceutically acceptable salts thereof, as well as preparation methods and uses of the compounds and pharmaceutical compositions comprising the compounds, stereoisomers, tautomers, deutero-derivatives or pharmaceutically acceptable salts thereof, wherein the compounds can be used as sodium channel subtype Nav1.8 inhibitors, and their pharmaceutical use in the treatment and prevention of pain-related disorders.

Provided herein are methods and compositions for reducing and preventing pain. In some embodiments, the methods include administration of a composition to an individual experiencing pain, the composition including one or more of Incarvillea sinensis, Salix alba, Tanacetum parthenium, Petasites hybridus, papain, and bromelain.

The present invention relates to safety shoes worn on the feet of a wearer, and more particularly to safety shoes that can prevent pain and injury to the feet and improve comfort for the wearer by ensuring space for the little toe to move through the internal space of the protrusion.

The invention discloses a compound shown in a general formula (I) or a general formula (II), a stereoisomer, a tautomer, a deuterated derivative or a pharmaceutically acceptable salt thereof, a preparation method and application of the compound, and a pharmaceutical composition containing the compound, the stereoisomer, the tautomer, the deuterated derivative or the pharmaceutically acceptable salt thereof, the compound can be used as a sodion channel subtype Nav1.8 inhibitor, and can be used as a medicine for treating and preventing pain-related diseases.

The present invention relates to a benzimidazolone-based cinnamamide derivative as a TRPV1 antagonist and a pharmaceutical composition for treating or preventing pain containing the same as an active ingredient. The example compounds provided in one aspect of the present invention block the activation of TRPV1 caused by capsaicin, a TRPV1 receptor activator, but induce appropriate inhibition at approximately pH 20% to 80%, thereby the compounds have pain-relieving effects and effectively reduce side effects such as abnormal body temperature.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

The present disclosure is directed to compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid, or a pharmaceutically acceptable salt thereof, for treating or preventing pain, for example migraine, in a subject, and methods which comprises administering the said compound, or the pharmaceutically acceptable salt thereof, respectively.

The present disclosure provides analgesic peptides. Also provided is a formulation comprising any one of the analgesic peptides and a pharmaceutically acceptable excipient. Also provided is a method for treating or preventing pain in a subject in need thereof, comprising administering to the subject an effective amount of any one of the analgesic peptides.

Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, that can inhibit HCN1 / HCN2 and are expected to have utility as therapeutic agents, for example, for treating inhibiting, or ameliorating pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of, pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus, and for preparing pharmaceuticals for this purpose.

The present invention relates to the field of analgesia. Concretely, the present invention provides compounds and pharmaceutical compositions, as well as their use in the treatment or prevention of pain. More particularly the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in the treatment or prevention in an animal, including a human, of pain.

The proposed group of inventions relates to the medical field, in particular to methods for the treatment, management, and prevention of pain using the tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycinamide (H-Tyr-D-Arg-Phe-Gly-NH2), and to pharmaceuticals based on this tetrapeptide. These can be used to treat acute or chronic pain, particularly in cancer patients and in the early postoperative period after various surgical procedures. A method for the treatment, management, and prevention of pain is proposed, which involves administering H-Tyr-D-Arg-Phe-Gly-NH2 in a single dose of 2 to 7 mg, not exceeding 42 mg per day, with at least 4 hours between doses, for a maximum pain treatment course of 96 days, with the possibility of repeating the course multiple times.

An aqueous composition for intranasal administration by spray including a mixture of (a) sufentanil, a salt and / or analogs thereof and (b) ketamine, a salt and analogs thereof in solution. Also, an aqueous composition for intranasal administration by spray including (a) sufentanil, a salt and / or analogs thereof in solution and an aqueous composition for intranasal administration by spray including (b) ketamine, a salt and / or analogs thereof in solution, for use in a method for the treatment or prevention of pain in a child. The composition is useful for treating or preventing pain in a child of 17 years or younger. The composition is delivered from a nasal spray device to treat or prevent the pain such as procedural pain in a child.